As colon cancer cases are on the rise among younger adults, particularly those in their 20s and 30s, many in the U.S. under 45 are finding it challenging to secure insurance coverage for colonoscopies. These procedures are crucial for detecting colon cancer.
The Affordable Care Act (ACA) mandates that insurance companies cover colonoscopies for individuals aged 45 and older, largely due to recommendations from the U.S. Preventive Services Task Force, according to Caitlin Murphy, a cancer epidemiologist and professor at the University of Chicago. Preventive screenings, like pap smears, are fully covered under the ACA.
However, for those under 45, symptoms such as rectal bleeding classify a colonoscopy as a diagnostic test rather than as preventive. This distinction means it might not receive the same level of coverage. Murphy emphasized that the insurance coverage for diagnostic procedures varies significantly from plan to plan.
The difficulty for younger individuals in obtaining a colon cancer diagnosis is concerning, especially as research indicates that the rates are climbing notably in those under 40. “The increase is proportionately much higher among younger adults compared to those in their 40s,” explained Paul Brennan from the International Agency for Research on Cancer. His findings reveal that while the risk of colon cancer generally grows with age, diagnoses among younger people are increasing, even as rates for those over 60 are decreasing.
Take Dominick, a 35-year-old software engineer from Florida, who found out about the coverage nuances the hard way. After experiencing alarming symptoms—changes in bowel habits, stomach discomfort, and weight loss—his doctor recommended a colonoscopy. Initially, his insurer agreed to cover it, but just hours before the scheduled procedure, he was informed that it wouldn’t be covered because it was labeled diagnostic.
“It was a terrifying moment. I had already done my prep,” Dominick recounted, explaining that getting ready for a colonoscopy involves a strict low-fiber diet and then a strong laxative to clear the system.
Ultimately, Dominick had to pay around $2,000 out of pocket for his procedure, putting it on a credit card since he had no cash on hand. The results showed a precancerous polyp, which he had removed. He expressed fear over what might have occurred if he hadn’t managed to afford the procedure.
Meanwhile, obtaining insurance approval for diagnostic colonoscopies can be a prolonged process. “It’s dreadful,” Murphy stated, noting that she hears frequently from individuals who have suffered symptoms for extended periods and end up in frustrating referral loops. Their issues are often misdiagnosed as hemorrhoids or attributed to other recent events like childbirth. “They just go from one doctor to another without proper evaluation. It seems like a solvable issue,” she added.
Both Murphy and Rebecca Siegel, an epidemiologist at the American Cancer Society, highlight a pressing question: should the recommended screening age be lowered? The answer isn’t straightforward. The age was only recently reduced to 45, and Siegel recalls the significant opposition when the American Cancer Society advocated for this in 2018.
“There were concerns that the risk was too low, that lowering the age might take screenings away from older adults who carry a heavier burden, and exacerbate disparities, particularly among young people of color,” she elaborated.
Since the age adjustment, they’ve noted that earlier screenings have likely aided patients in catching their cancers sooner. Nonetheless, Siegel cautioned, “This isn’t a decision taken lightly.” The availability of gastroenterologists is limited, and the procedure itself carries risks.
For those under 45 battling to get insurance approval while facing symptoms, using a stool test like Cologuard might expedite the process, as suggested by Murphy and Siegel. Ideally, anyone presenting with rectal bleeding should get immediate approval for a colonoscopy.
They both advocate for increased awareness regarding colon cancer symptoms and emphasize the need for research into its causes. Murphy speculated there are likely “thousands of possibilities” contributing to the spike in colon cancer rates, advocating for research approaches that could help identify the top causes effectively.
One promising direction involves exploring the “exposome,” explained Murphy. This term refers to a comprehensive understanding of all environmental exposures throughout a person’s life. Advances in mass spectrometry now allow researchers to analyze many of these exposures from small blood or plasma samples.
“From a broad perspective,” Murphy remarked, “we need to be cautious. Lowering the screening age should not come at the expense of neglecting what might be causing this issue.”
